BIO Macau 2027
A curated platform selection event exclusive to decision-makers
January 21–22, 2027 in Galaxy International Convention Center, Macau, China, BIO Macau 2027 is not a typical biotech trade show. There will be no exhibitor booths or general admission seats. Attendees include BD and R&D decision-makers from over 10 of the world’s Top20 MNC, leading global venture funds, top Chinese innovative biotechs, and high-quality technology platform enterprises worldwide vetted by the review committee.
This summit operates on an invitation-only basis, open to VPs and C-suite executives. A professional review panel — comprising representatives from MNC, leading global investment funds and premier domestic innovative biotechs — collaborates with Haomai Technology to identify promising projects. Pre-summit engagements, on-site 1-on-1 meetings, and live pitches for selected projects will be arranged.
Focus Areas
Novel therapeutic modalities with differentiated strengths: TCE, ADC, RDC, proximity-induced technology, extrahepatic oligonucleotide delivery, AOC, oral/long-acting peptides, oral/long-acting antibodies, FIC small molecules, in vivo cell therapies and other cutting-edge therapeutics.
Why Attend
- Buyers on the panel: Experts from AZ, Eli Lilly, Roche, Novo Nordisk, Novartis, MSD, Bayer, Boehringer Ingelheim and Johnson & Johnson have confirmed or received invitations to join the review committee. Discuss evaluation criteria and potential deals face-to-face.
- Consensus-building Brainstorming: Four key frontier technology streams for interactive breakout discussions. Decision-makers share forward-looking perspectives to forge actionable industry consensus.
- Pitching integrated with deal discussions: Shortlisting is based on BP review by the committee. Shortlisted candidates gain access to pre-event communications plus on-site 1-on-1 meetings, with selected projects delivering live pitches.
- Macau’s Strategic Advantage: Against a shifting geopolitical backdrop, Macau acts as an international hub for clinical research, patient samples and data circulation. Policy interpretation and implementation pathways will be presented at the exclusive Galaxy Night Gala Dinner.
BIO Macau 2027: Selecting platforms, facilitating transactions, defining eligibility for entry into the next wave of frontier therapeutic tracks.
Roadshow Application
shiyulong@hq-haomai.com
daiyan@hq-haomai.com
*The Review Committee will review each company’s profile and BP quality to determine roadshow eligibility. Shortlisted applicants will be notified via email.
